Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

EASY FOR THEM.*1,2
EASY FOR YOU.2

Introduce your patients to better glucose management*†1,2,3 with the FreeStyle Libre 2 system. The CGM solution, with unsurpassed 14-day accuracy4 that's easy for you and your patients*1 and has optional, real-time glucose alarms‡4.

NOW YOU KNOW

Learn More

Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

The #1 continuous
glucose monitor (CGM) in the US§

Whether your patients meet A1c goals*5 or not, they may experience significant time outside of range*6.
The FreeStyle Libre 2 system safely and effectively replaces BGM and now has glucose alarms‡4.

UNSURPASSED 14-DAY ACCURACY4

  • Outstanding accuracy in the low-glucose range4 when it matters the most
  • No fingersticks required even when glucose is low, falling, or rapidly changing

REAL-TIME ALARMS WITHOUT SCANNING

  • Excellent, reliable alarm performance in the low-glucose range4
  • The first and only 14 day glucose monitoring system with alarms‡4

EASY FOR YOU AND YOUR PATIENTS*1,2

  • Measures real-time glucose every minute4 and optional glucose alarms are sent straight to your patient's reader
  • More affordable CGM at one-third the cost of other CGMs¶7
  • Easy to prescribe# with no prior authorizations required
Freestyle Libre 2 System

FreeStyle Libre 2 system Is Indicated For Patients With Diabetes Age 4 And Older

Parents and caregivers can rely on the FreeStyle Libre 2 system to make treatment decisions without confirmatory fingersticks even when glucose is low or falling4

Easy to prescribe#

Prescriptions can be filled without paperwork hassles or prior authorization at participating pharmacies

Improved Diabetes Outcomes

Both real-world evidence and clinical trial results highlight the benefits of FreeStyle Libre portfolio*,1-2,8-12

* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.

† Compared to self-monitoring blood glucose testing.

‡ Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.

§ Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.

‖ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

¶ Based on a comparison of list prices of FreeStyle Libre 2 system versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

# No paperwork hassles or prior authorization needed at participating pharmacies. This applies to commercially insured patients. This does not apply to beneficiaries of Medicare, Medicaid, or other federal or state healthcare programs. Participating pharmacies are subject to change without notice.

References: 1. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (February 2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6. 2. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study." Pediatr Diabetes 19, no. 7 (November 2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 3. Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 10057, no. 388 (September 2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 4. Freestyle Libre 2 User's Manual. 5. Hirsch, Irl B., and Eugene E. Wright. "Using flash continuous glucose monitoring in primary practice." Clinical Diabetes 37, no. 2 (April 2019): 150-161. https://doi.org/10.2337/cd18-0054. 6. Battelino, Tadej, et al. “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.” Diabetes Care 42, no. 8 (August 2019): 1593-1603. https://doi.org/10.2337/dci19-0028. 7. Data on file. Abbott Diabetes Care. 8. Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 10057, no. 388 (September 2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 9. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (January 2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 10. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (January 2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 11. Miller, Eden, et al. "85-LB: Freestyle Libre System Use Associated with Reduction in Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes without Bolus Insulin." Diabetes 69, supp. 1 (June 2020). https://doi.org/10.2337/db20-85-LB. 12. Hirsch, Irl B. et. al. "Utilization of Continuous Glucose Monitors is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events Regardless of Prior Blood Test Strip Usage." Diabetes 69, supp. 1 (June 2020). https://doi.org/10.2337/db20-875-P.

ADC-12852 v9.0 7/21